Selective inhibition of group II phospholipase A2 by quercetin
- 1 October 1993
- journal article
- Published by Springer Nature in Inflammation
- Vol. 17 (5) , 573-582
- https://doi.org/10.1007/bf00914195
Abstract
The influence of quercetin, chlorpromazine, aristolochic acid, and indomethacin on group I phospholipase A2 (PLA2) from porcine pancreas and on group II PLA2 fromVipera russelli was compared. Quercetin and chlorpromazine were found to inhibit PLA2 activity in lower concentrations (< 100μM), while aristolochic acid and indomethacin were inhibitory only in higher concentrations (> 100μM). The order of potency againstVipera PLA2 was: quercetin >chlorpromazin aristolochic acid > indomethacin, while the order of potency against pancreatic PLA2 was: chlorpromazine > aristolochic acid > indomethacin> quercetin. Thus, quercetin was a potent inhibitor towards group II PLA2 (IC50=2μM), but a very weak inhibitor against group I PLA2, with maximum 30% inhibition. Aristolochic acid and indomethacin were three to four times more potent towards group II PLA2 than towards group I PLA2, while chlorpromazine was equally potent towards the two PLA2 types. Quercetin and chlorpromazine were also tested against two PLA2 fractions purified from the plasma of septic shock patients; chlorpromazine was then equally potent towards the two PLA2 fractions, whereas quercetin was a potent inhibitor of only one of the two PLA2 fractions (IC50=4μM). Together, these results indicate that (1) different PLA2 inhibitors have different potency depending on which type of PLA2 they are used against, (2) quercetin selectively inhibits group II PLA2 and may therefore be used to discriminate between different PLA2 forms in biological materials, and (3) both PLA2 of group I and group II are present in septic shock plasma.Keywords
This publication has 24 references indexed in Scilit:
- Serum phospholipase A2 enzyme activity and immunoreactivity in a prospective analysis of patients with septic shockLife Sciences, 1992
- Eicosanoid generation from antigen‐primed mast cells by extracellular mammalian 14‐kDa group II phospholipase A2FEBS Letters, 1991
- Isolation and characterization of phospholipase A2 from rat lung with affinity chromatography and two-dimensional gel electrophoresisBiochimica et Biophysica Acta (BBA) - Lipids and Lipid Metabolism, 1989
- Pharmacologic modulation of D-49 phospholipase A2-induced paw edema in the mouseInflammation Research, 1989
- Serum phospholipase — Regulatory and pathophysiological aspectsJournal of Molecular Medicine, 1989
- Role of phospholipase A in multiorgan failure with special reference to ARDS and acute renal failure (ARF)Journal of Molecular Medicine, 1989
- Effects of aristolochic acid on phospholipase A2 activity and arachidonate metabolism of human neutrophilsBiochimica et Biophysica Acta (BBA) - Lipids and Lipid Metabolism, 1989
- Inhibition of human non-pancreatic phospholipases A2 by retinoids and flavonoids. Mechanism of actionInflammation Research, 1988
- Extracellular phospholipase A2: causative agent in circulatory collapse of septic shock?Inflammation Research, 1988
- Potential therapeutic efficacy of inhibitors of human phospholipase A2 in septic shockInflammation Research, 1986